AbstrAct subclinical hypothyroidism (scH), defined as elevated serum thyroid-stimulating hormone (tsH) in the presence of normal circulating free thyroxine (Ft4) and triiodothyronine (t3), is a relatively common condition. replacement treatment with levothyroxine is justified only for individuals with tsH levels >10 mIU/l. serum lipid levels are influenced by thyroid status and there is evidence pointing to a link between scH and an unfavorable lipid profile. Despite some conflicting data, most studies suggest that levothyroxine treatment may exert a beneficial effect on the lipid profile in scH regarding mainly total cholesterol and low-density lipoproteincholesterol. Moreover, it appears that treatment may also improve some other markers associated with cardiovascular (cV) disease such as carotid intima media thickness ( 17-03-201317-03- , Accepted 20-10-2013 Review (FT4) and triiodothyronine (T3) levels within the reference range.
tion and the lipid profile with overt hypothyroidism being strongly related to dyslipidemia. 7, 8 Because of diminished numbers of low-density lipoprotein (LDL) receptors in the liver, the fractional excretion of LDLcholesterol (LDL-C) is reduced in hypothyroidism. Moreover, cholesterol oxidation is enhanced in hypothyroidism. 9 It appears that total cholesterol (TC) and LDL-C concentrations are positively correlated with TSH in the general population independent of thyroid status. 10 Furthermore, there is a well established association between dyslipidemia and increased cardiovascular (CV) risk. 11 Therefore, it is of interest to assess the relationship between SCH and an adverse lipid profile and to establish whether levothyroxine treatment can reduce any associated CV risk.
MEtHodS
We searched PubMed up to 10 January 2013 using combinations of the following keywords: subclinical hypothyroidism, dyslipidemia, hypercholesterolemia, lipids, cardiovascular disease, atherosclerosis, endothelial dysfunction, treatment, levothyroxine. Randomized controlled trials, original papers and review articles were included. References of these articles were scrutinized for additional relevant articles.
rESuLtS

SCH and Dyslipidemia
Epidemiological population-based studies suggest a link between SCH and an unfavorable lipid profile. In the Colorado Study, 25,852 individuals with SCH had significantly higher TC and LDL-C concentrations compared with euthyroid subjects (p <0.001).
2 TSH and lipid levels were associated in a dose-dependent manner [p for trend <0.001 for TC and LDL-C and 0.02 for triglycerides (TG)]. Consistently, in another community-based study (n = 2108), TC and LDL-C levels were higher among individuals with SCH than euthyroid participants (although the comparison for TC was borderline non-significant after adjustment for age and sex; p = 0.06). 10 A study based on an Indian population (n = 5343) included both adults and children/adolescents. 12 The prevalence of SCH was 13.5%. When SCH subjects were divided into 2 groups using a TSH cut-off point of 10 mU/l, those with a TSH level below this value showed no lipid abnormalities. On the other hand, patients with TSH concentrations >10 mU/l had significantly greater levels of TC and LDL-C (p <0.0001 for both) as well as lower HDL-C (p = 0.001) compared with controls. TSH positively correlated with TC (r = 0.037; p = 0.007) and LDL-C (r = 0.028; p = 0.037) but negatively with HDL-C (r = 0.031; p = 0.018) in the whole study population. In another study including elderly participants (n = 2799), SCH (n = 62) was associated with higher TC levels compared with the euthyroid state only among black women (p <0.001). 13 Nevertheless, higher TSH levels were associated with higher TC concentrations in the entire cohort.
In line with the above, findings from several smaller studies indicate an association between dyslipidemia and SCH. [14] [15] [16] [17] [18] Overall, TC and LDL-C are particularly affected. It appears that increased TSH levels are associated with dyslipidemia without a cut-off threshold for this relation, with dyslipidemia being more prevalent with increasing degree of thyroid hypofunction. 19 It has also been suggested that SCH is associated with an intermediately adverse lipid profile between that of euthyroid individuals and that of patients with overt hypothyroidism. 20 Other factors such as insulin resistance and smoking may augment the adverse effect of TSH on lipids. 21 Moreover, serum lipids may be significantly affected by thyroid function even in euthyroid subjects. In individuals with no history of thyroid abnormalities or relevant treatment, TSH within the normal range positively correlated with TC (p = 0.001), TG (p = 0.001) and LDL-C (p = 0.003) even after adjustment for confounding factors (e.g. age, sex and obesity). 22 TSH concentrations also linearly correlated with TC, non-HDL-C and TG levels (β = 0.173, 0.181 and 0.103, respectively; p <0.01) in euthyroid non-smokers with CHD (n = 406). 23 It should be noted that some studies have reported increased levels of lipoprotein (a) [Lp(a)] associated with SCH, 14, 15, 24 but others did not confirm this finding. 14, 25 Lp(a) has been considered as an independent risk factor for cardiovascular events. 26 Nevertheless, other studies have yielded conflicting findings, indicating either no difference in lipid profile between SCH and euthyroid status [27] [28] [29] [30] or an association of SCH with lipid variables other than TC and LDL-C. 4, 31, 32 In National Health and  Nutrition Examination Survey III (NHANES III) , a large population-based study, subjects with SCH (n = 215) showed no significant differences in lipid parameters compared with euthyroid individuals (n = 8013) when adjusted for age, race, sex and the use of lipid-lowering agents. 27 Neither logistic regression analysis (distinguishing between normal or abnormal lipid levels) nor linear regression analysis (testing a continuous relationship between lipid and TSH levels) demonstrated any significant association. 27 Consistently, among 1212 individuals, those with SCH (n = 249) did not differ from euthyroid controls (n = 963) regarding their lipid profile [except for TG levels which were significantly higher (p <0.001)]. 4 It is of interest that postprandial lipemia was the only adverse feature of lipid profile associated with SCH as reported in a small study. 31 Postprandial lipemia, i.e. increased non-fasting TG concentration, is considered a CV risk factor. 33, 34 In this study, 31 TC, LDL-C, verylow-density lipoprotein-cholesterol (VLDL-C) and TG levels of patients with overt hypothyroidism (OH) (n = 25) or SCH (n = 27) were similar to controls; however, mean TG concentrations at postprandial 8 th hour were significantly greater in patients with OH and SCH compared with their euthyroid counterparts (p = 0.017 and p = 0.049, respectively). TSH concentrations positively correlated with postprandial 8 th hour concentrations of TG (r = 0.320; p = 0.008), TC (r = 0.247; p = 0.03) and VLDL-C (r = 0.278; p = 0.022). We should note that patients did not differ from controls with regard to measures of glucose tolerance that could confound findings of postprandial lipemia.
In another study, middle-aged women with SCH (n = 95) did not differ from controls (n = 65) with regard to TC and LDL-C concentrations but had significantly higher TG and lower HDL-C levels. In addition, higher values of TSH (>10 mIU/l) were associated with an atherogenic pattern B of LDL-C subfractions (i.e. small dense LDL particles) compared with lower TSH (<5 mIU/l). Small dense LDL particles are associated with enhanced atherogenicity and, therefore, increased CV risk. 35, 36 A link between small dense LDL and OH has been previously suggested.
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In this study, 32 B LDL profile was more prevalent among patients with TSH >10 mIU/l (30%) than in those with TSH, ranging from 5 to 10 mIU/l or <5 mIU/l (13.6 and 5.9%, respectively).
There is also some evidence implying a link between SCH and the presence of metabolic syndrome (MetS). 22, 38, 39 However, further studies failed to confirm such an association. [40] [41] [42] Finally, regarding the importance of non-traditional CV risk factors (such as thrombotic markers and arterial stiffness), these remain to be elucidated since data are not conclusive.
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Effect of Levothyroxine Treatment
Several studies assessed the effect of levothyroxine replacement treatment on the lipid profile in patients with SCH.
In a systematic review data from 13 studies, 247 subjects were analyzed regarding lipid changes after thyroxine therapy for SCH. 54 Among populations studied there were individuals with untreated mild thyroid failure (consistent with the definition of SCH) as well as patients with a history of overt hypothyroidism receiving suboptimal levothyroxine therapy, insufficient to normalize TSH levels. Treatment duration was at least 12 weeks. Information on TC levels was reported in all 13 studies, while data on TG, LDL-C and HDL-C levels were provided in 12, 10 and 9 studies, respectively. Overall, small but significant reductions were reported in TC [7.9 mg/dL; 95% confidence interval (CI), 3.3 to 13] and LDL-C (10 mg/dL; 95% CI, 4.0 to 16) levels. Considerable heterogeneity was found among studies. Nevertheless, use of a random effects model yielded similar results. Among studies, two showed no significant change in TC and LDL-C. There was a positive correlation between the change in TC levels and its initial concentration (r = 0.55). Moreover, the change in TC levels was greater for patients with suboptimally treated overt hypothyroidism after normalization of TSH levels than for those with untreated SCH (p <0.05). Changes in TG and HDL-C concentrations were not significant. Heterogeneity among studies was accounted for in analyses. 54 Consistently, a former review had demonstrated a decline of 0.4 mmol/l (15.5 mg/dl) (95% Cl 0.2-0.6 mmol/l) in TC levels after normalization of TSH levels following levothyroxine therapy in SCH. 55 This reduction was not correlated with pre-treatment TC concentrations. Meanwhile, the respective reduction observed in patients with overt hypothyroidism was greater and positively associated with TC levels at baseline.
In a randomized double-blind placebo-controlled trial, 12-month levothyroxine treatment with 31 patients (achieving a period of euthyroidism of at least 4 months) resulted in significant reductions in TC and LDL-C levels (3.8%; p = 0.015 and 8.2%; p = 0.004, respectively, compared with placebo (n = 32). 56 Treatment with levothyroxine also achieved a slight but significant decrement in apolipoprotein (apo) B-100 concentrations. Nevertheless, comparing the mean treatment effect of levothyroxine vs placebo did not yield a significant difference. Replacement therapy achieved greater lipid reductions in patients with higher baseline TSH (12 mIU/l) and TC, LDL-C concentrations. Consistently, 1 year after restoration of euthyroid status by levothyroxine replacement therapy, 11 patients had significantly reduced TC and LDL-C levels compared with those on placebo (n = 15). 20 In line with the above, in another trial (n = 100) with a crossover design (patients changed to the opposite treatment arm i.e. thyroxine vs placebo after 12 weeks), TC and LDL-C concentrations were reduced by 5.5% (p <0.0001) and 7.3% (p = 0.05), respectively. 57 A lipid evaluation 6 months after TSH normalization with levothyroxine treatment in patients with SCH (n = 49) showed a decline in TC and LDL-C values (8 and 10.2%, respectively; p = 0.003 for both). 14 The absolute lipid reductions positively correlated with the baseline TC and LDL-C concentrations (r = 0.43, p = 0.05 and r = 0.54, p = 0.01, respectively). Moreover, there was a positive association between TC and LDL-C decrements and baseline TSH levels (r = 0.54, p= 0.01 and r = 0.57, p= 0.005, respectively) as well as with the reduction in serum TSH (r = 0.59, p= 0.002 and r =0.60, p= 0.002, respectively).
14 Another 6-month intervention study also showed that TC and LDL-C levels were reduced by 10.5% (p <0.01) and 14.7% (p <0.001), respectively, after levothyroxine treatment. 58 Moreover, after 3 months of stable euthyroid status subsequent to levothyroxine treatment, elderly patients with SCH (n = 25) experienced significant improvement in most lipid parameters (except for HDL-C). 59 Elderly patients (65 years and older) with OH (n = 31) included in the same study showed similar changes in lipid profile with an additional improvement in HDL-C. 59 Accordingly, 6-month treatment with levothyroxine and normalization of TSH ameliorated the adverse lipid profile of elderly women with SCH (n = 17). 60 Concentrations of TC (p = 0.017), LDL-C (p = 0.014), TC/HDL-C (p = 0.05), TC/LDL-C (p = 0.03), Lp(a) (p = 0.0005) and apoB (p = 0.013) were significantly reduced; however, apoAI levels were also decreased and HDL-C was reduced but not significantly. In another study (n = 42), levothyroxine treatment conferred small but significant reductions in TC (p <0.05), LDL-C (p <0.01) and apoB (p <0.01) levels, but failed to improve a series of emerging cardiovascular risk markers such as homocysteine, C-reactive protein (CRP) and Lp(a). 61 Also, long-term (18 months) levothyroxine treatment significantly reduced TC (p = 0.023), LDL-C (p = 0.018) and Lp(α) (p = 0.005) levels in a female population with SCH, reaching values similar to healthy controls. 24 Favorable lipid effects of levothyroxine replacement therapy in SCH patients regarding especially TC and LDL-C levels have also been shown in several small studies. 16, 62, 63 Nevertheless, some other studies have yielded variable results inadequate to support a clear-cut lipid benefit of levothyroxine replacement treatment in SCH. In an intervention trial, part of the 5 th Tromso study, no significant lipid reductions were noted in SCH treated with levothyroxine (n = 32) compared with placebo (n = 32). 64 However, a subanalysis of data only for those with post-treatment TSH levels of 0.2-1.99 mIU/l (reference range 0.5-3.5 mIU/l) yielded significant reductions in TC (5%; p <0.05), LDL-C (9%) and apoB (8%; p <0.01 for both). Moreover, there are data showing significant TC and LDL-C reductions after levothyroxine replacement therapy only among SCH patients with pre-treatment TC levels exceeding 240 mg/dl 15 or TSH >10 μU/ml. 15, 17 Other results showed that levothyroxine treatment significantly reduced TC, non-HDL-C, remnant-like particle (RLP)-C and apoB levels in SCH patients but not LDL-C, although normalization of serum TSH had been achieved. 65, 66 On the other hand, there are also several studies demonstrating no significant benefit in lipid profile in patients with SCH receiving levothyroxine treatment.
47, [67] [68] [69] [70] [71] Overall, it appears that the beneficial effect-if any-of levothyroxine treatment on lipid profile in SCH mainly concerns TC and LDL-C levels. TG concentrations are not significantly affected. As far as HDL-C is concerned, most studies demonstrate no significant effect of levothyroxine substitution on HDL-C concentrations in SCH. 16, 18, 20, 24, 47, [60] [61] [62] [63] [65] [66] [67] 69, 70 Nevertheless, there is limited evidence suggesting either a lowering 15, 17, 59, 72 or an increasing effect.
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SCH and CV Disease A link between hypothyroidism and atherosclerosis was first suspected more than a century ago. 74 The first data came from autopsy studies which described increased atherosclerotic burden in hypothyroid patients. Since then, several studies have evaluated CV outcomes as well as subclinical markers of atherosclerosis yielding variable results.
Evidence regarding the association of SCH and the risk of CV disease appear conflicting in epidemiological studies. The Cardiovascular Health Study, a community-based study (n = 3233), showed no increased incidence of fatal or non-fatal CV events in individuals with SCH (n = 496). 75 Another population study (n = 2730) showed an increased risk for heart failure but not for any atherosclerotic events and mortality associated with SCH (n = 338). 76 Further data have also failed to conclusively demonstrate an increased risk for CVD in older patients and postmenopausal women with SCH. 77, 78 In contrast, a meta-analysis of 15 studies showed an increased prevalence and incidence of coronary heart disease (CHD) in patients with SCH compared with euthyroid individuals; nevertheless, this was true only among subjects younger than 65 years (OR 1.57, 95% CI 1.19 -2.06; p = 0.001 and OR 1.68, 95% CI 1.27 -2.23; p = 0.001, respectively). 79 Moreover, these younger individuals with SCH had an increased risk for CV death (OR 1.3795% CI 1.04 -1.79; p = 0.02) compared with those with normal thyroid function. This is in line with other findings demonstrating SCH as an independent predictor for CV disease in younger men (<50 years of age). 4 Consistently, another study (n = 2856) demonstrated an increased risk for CHD in individuals with SCH (n = 292) compared with euthyroid subjects (OR 2.6; 95% CI, 1.2 -5.6; p = 0.02 after adjustment for age and sex).
28 This association lost significance for women in a separate gender analysis. Significance of these relations in the entire cohort and men was preserved after adjustment for other CV risk factors (e.g. smoking, lipid levels and blood pressure). 28 In another community-based study, CHD was significantly more prevalent among patients with SCH (n = 119) than euthyroid individuals (n = 1906) even after adjustment for conventional CV risk factors (OR 2.2, 95% CI 1.2 -4.0; p = 0.01). 80 Longitudinal data from the same study for subjects without CHD at baseline showed an increased hazard ratio (HR) for coronary events in those with SCH (n = 101; HR 1.7, 95% CI 1.2 -2.4; p <0.01) compared with euthyroid persons (n = 1752). 80 Other non-traditional CV factors such as plasma viscosity, endothelial dysfunction, CRP and mean platelet volume (MPV) may also be affected in SCH.
53,81-84 Whether a "dysfunctional" HDL 85 plays a role in any potential link between SCH and CV risk remains to be established.
Effect of Levothyroxine Treatment on Other Cardiovascular Risk Markers
In addition to the relationship between SCH and an unfavorable lipid profile, other markers associated with CV risk can be adversely affected in SCH. Levothyroxine administration in SCH patients may have an additional ameliorating effect on such markers, even-in some instances-in the absence of a concomitant effect on lipid profile.
Overt hypothyroidism is associated with surrogate markers of atherosclerosis such as carotid intima media thickness (cIMT). 86, 87 Increased values of cIMT have been reported in patients with SCH compared with euthyroid individuals. 62, 86 This relation may be mediated by classical cardiovascular risk factors such as hypertension, hyperlipidemia commonly associated with SCH as well as high TSH levels per se. 88 There is some evidence suggesting a beneficial effect of levothy-roxine replacement therapy on cIMT in subjects with SCH. In particular at 6 months of stable euthyroidism achieved by levothyroxine treatment, cIMT displayed a mean reduction of 0.09 mm (95% CI 0.06 -0.11) or 10%. 62 Mean cIMT values positively correlated with TSH levels (r = 0.51, p = 0.0008). There was also a significant positive association between the absolute reduction in mean cIMT and that in serum TC and TSH concentrations (r = 0.35, p = 0.02 and r = 0.61, p = 0.0001, respectively). 62 Consistently, following 1 year of euthyroidism with levothyroxine therapy, cIMT was significantly decreased by 0.07 ± 0.06 mm (p = 0.021) in patients with SCH (n = 20). 16 Similarly, treatment with levothyroxine and normalization of thyroid function conferred a decrease of 0.08 mm in cIMT in another study (n = 40). 86 A small but significant decrease in cIMT (mean 0.01, p = 0.008) has also been noted after a shorter period (3 months) of euthyroidism achieved by levothyroxine substitution in SCH patients (n = 38). 72 This reduction was not related to concomitant change in other variables such as lipids.
Consistently, a similar mean decrement in cIMT (13%; 0.01 mm, p = 0.046) was achieved after 18 months of levothyroxine therapy in a female population with SCH (n = 20). 24 In addition, blood pressure (BP) was improved (p = 0.001 for systolic BP and p = 0.005 for diastolic BP) and renal function indices (i.e. serum creatinine, cystatin C and estimated glomerular filtration rate (eGFR) (p = 0.001 for all) were enhanced following levothyroxine replacement therapy. The mean common carotid artery diameter, baseline brachial artery diameter as well as glyceryl trinitrite-mediated diameter all significantly increased (p <0.05) after levothyroxine treatment. However in this study the period of stable euthyroidism with treatment is not reported.
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One study compared the effect of statin therapy to that of levothyroxine replacement in SCH patients. 68 Patients allocated to levothyroxine (n = 20) exhibited a decrement in mean cIMT comparable to that conferred by simvastatin treatment (n = 20). Levothyroxine replacement therapy exerted no beneficial effect on lipid profile in contrast to statin therapy. Therefore, the cIMT reduction associated with levothyroxine replacement cannot be attributed to improved lipid parameters. 68 On the other hand, 1-year treatment with levothyroxine conferred no improvement in cIMT in women with SCH (n = 32), 67 but decelerated the deterioration in brachial artery flow-mediated dilatation (FMD), an effect also noted in the study group receiving no treatment. Moreover, there is additional evidence suggesting a beneficial effect of levothyroxine treatment on endothelial function in SCH. Twelve-week levothyroxine replacement improved brachial artery FMD in patients with SCH (n = 100) vs placebo (5.9 vs 4.2%; p = 0.001). 57 Several other markers of endothelial function (e.g. forearm blood flow response to intrabrachial acetylcholine, response to sodium nitroprusside and minimal forearm vascular resistance) also appear to improve by levothyroxine administration in subjects with SCH (n = 14). 89 Serum asymmetrical dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), as well as CRP and L-arginine levels can be increased in SCH, while nitric oxide production is decreased compared with controls. 18 These markers were significantly (p <0.05 for all) improved after 1 month of stable euthyroidism following levothyroxine treatment, although lipid profile was not affected. Unexpectedly, SCH patients in this study were found to have lower small dense LDL levels than controls. These were increased by levothyroxine substitution, while TC and LDL-C concentrations were not affected. 18 A novel marker of CV risk, low circulating endothelial progenitor cells (EPC), has also been related to SCH independently of lipids and other variables (n = 20). 90 EPC number increased after levothyroxine treatment, whereas no significant amelioration of lipid profile (except for a small increase in HDL-C) was noticed.
Several studies have examined the importance of other parameters associated with the atherosclerotic process (such as inflammatory and thrombotic markers or endothelium-related molecules) in SCH and the effect of levothyroxine replacement on them. However, no significant benefit has been demonstrated. 24, 47, 61, 72 There is considerable evidence suggesting that levothyroxine replacement therapy in SCH may improve the lipid profile. This ameliorating effect regards mainly TC and LDL-C. Nevertheless, this was not confirmed in all studies.
The studies presented in this overview have several limitations. First, there are discrepancies among the populations studied in terms of their characteristics (e.g. age, gender, body mass index, comorbidities and SCH etiology). Some studies included only younger individuals, 14, 62 others recruited only elderly people, 59, 60 while most of them had no age cut-offs. Some studies included only women. 24, 67, 71 The etiology of SCH was mentioned in some studies 17, 62, 65, 66 but not in others, 15, 59, 71, 72 while percentages of certain SCH causes differed among populations. Furthermore, conditions which affect lipid metabolism were not taken into consideration in either patient selection or data analysis in some studies. 17, 59, 69 Diabetic individuals were excluded from most studies but insulin resistance, an important determinant of lipid metabolism, was not accounted for. In addition, different treatment time periods and levothyroxine dose were used. In many cases, it was not reported whether 17, 63 or for how long 24,65,66 euthyroidism had been restored before post-treatment measurements.
Other less well established links between SCH and vascular risk
There is some evidence implying an increased CV risk in SCH but a clear association between SCH and CV disease has yet to be firmly established. SCHrelated autoimmunity has been suggested as being implicated in the development of atherosclerosis in these patients; 91, 92 however, further studies did not support this. 93, 94 An increased MPV has been reported in SCH. 53 This was reversed on achieving euthyroid status. In addition, MPV has been linked to low-grade inflammation and thrombosis risk. 95 In this context, in an adult Taiwanese population SCH was associated with elevated high sensitivity CRP (hsCRP) quartiles, suggesting a link with inflammatory status. 96 Although there is no evidence that antioxidants reduce vascular risk, it is of interest that severity of hypothyroidism appears to contribute to the antioxidant deficiency and oxidant stress. 97, 98 SCH is related to non-alcoholic fatty liver disease (NAFLD) in a dose-dependent manner independently of metabolic risk factors. 99 Moreover, NAFLD and abnormal liver tests are associated with an increased risk of vascular events. [99] [100] [101] [102] The link between NAFLD and SCH may, at least in part, be due to decreased hepatic very-low-density lipoprotein (VLDL)-TG secretion that occurs in hypothyroidism. 103 The association between SCH and MetS may also be relevant since NAFLD is the hepatic expression of MetS. 104, 105 It is also of interest that epicardial fat, another form of abnormal fat accumulation, is associated with SCH, NAFLD, MetS and vascular risk. 106, 107 There is more to BP assessment than just occasional office-based measurements. Therefore, it is of interest that raised TSH levels have been linked to decreased nocturnal BP-dipping. 108 Similarly, a meta-analysis (SCH = about 1783 patients; euthyroid about 15,540 patients depending on which subgroups were analyzed) reported that SCH was associated with both raised systolic and diastolic BP. 109 Chronic kidney disease (CKD) is now recognized as another condition associated with a high risk of vascular events. 110, 111 Therefore, it is of interest that thyroid hormone therapy preserved renal function and was also an independent predictor of renal outcome in CKD patients with SCH. 112 The relationship between SCH and vascular risk possibly extends to treatment since thyroid status increases the risk of myositis in patients taking statins.
concLuSIonS
A possible role for levothyroxine replacement therapy in SCH-associated dyslipidemia could be reasonable in an effort to eventually reduce CV risk. Recent findings have demonstrated an ameliorating effect of levothyroxine treatment on markers of subclinical atherosclerosis, such as cIMT, indices of endothelial dysfunction and several other predictors of vascular risk. However, so far there are insufficient data to support an undisputed benefit of levothyroxine treatment in SCH in terms of CV disease prevention. Therefore, further investigation is warranted. There is a need for intervention studies to assess the effect of levothyroxine treatment on clinical outcomes (i.e. CV events) rather than just laboratory measurements in SCH. In view of all the numerous documented links between SCH and predictors of vascular risk (see above), such studies will need to include very large numbers of patients to enable effective matching as well as multivariate analyses. It may, however, be very difficult to fund such trials. Furthermore, the complex interaction between SCH and predictors of vascular disease may also explain the variability of the results obtained from studies that assessed vascular events or even changes in some biochemical, functional or structural variables associated with an increased risk of vascular events. Finally, with a relative risk of vascular death (after correction for several vascular risk factors) of 1.68 (95% CI: 1.02 -2.76) in patients with SCH (compared with those who were euthyroid) over a 10-year period, 114 we need to consider whether SCH should be classed as a CHD equivalent when this condition occurs in the presence of other vascular risk factors.
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